Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540161 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Annick Desjardins.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02540161: Completed Phase 2 study, sponsored by Annick Desjardins.
NCT02540161 is a Phase 2 study that has completed, run by Annick Desjardins. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02540161, a Phase 2 study, has completed, sponsored by Annick Desjardins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified. This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glioma (glioblastoma or gliosarcoma) in two cohorts to assess the efficacy of Sym004.
Primary Outcome
Within each cohort, the percentage of participants alive and progression-free at 6 months after the start of Sym004 treatment will be determined. PFS6 will be calculated from the date study treatment started until the date of progression or death, or the date of last follow-up if participants are alive without progression. Kaplan-Meier methods will be used to estimate survival.
Interventions
- DRUG Sym004 - 18 mg/kg
- DRUG Sym004 - 24 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 2 |
What the finished NCT02540161 record still lists
NCT02540161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Sym004 - 18 mg/kg is the first listed.
NCT02540161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02540161 about?
NCT02540161 is a clinical study titled "Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma". The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified. This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glio...
What is the current status of trial NCT02540161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-02-01. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT02540161?
The interventions under investigation include: Sym004 - 18 mg/kg (DRUG), Sym004 - 24 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02540161?
This trial is sponsored by Annick Desjardins, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02540161's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI